Tandem Capital Management Corp ADV Has $5.03 Million Stock Position in Stryker Co. (NYSE:SYK)

Tandem Capital Management Corp ADV decreased its holdings in Stryker Co. (NYSE:SYK) by 3.4% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 16,795 shares of the medical technology company’s stock after selling 589 shares during the quarter. Stryker accounts for approximately 3.1% of Tandem Capital Management Corp ADV’s holdings, making the stock its 5th largest position. Tandem Capital Management Corp ADV’s holdings in Stryker were worth $5,029,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of SYK. Farmers & Merchants Trust Co of Chambersburg PA boosted its stake in Stryker by 203.3% during the fourth quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company’s stock valued at $27,000 after buying an additional 61 shares in the last quarter. HBC Financial Services PLLC bought a new position in Stryker during the fourth quarter valued at about $37,000. Bourgeon Capital Management LLC bought a new position in Stryker during the fourth quarter valued at about $37,000. Operose Advisors LLC lifted its holdings in shares of Stryker by 308.6% during the third quarter. Operose Advisors LLC now owns 143 shares of the medical technology company’s stock valued at $39,000 after purchasing an additional 108 shares during the last quarter. Finally, Venturi Wealth Management LLC lifted its holdings in shares of Stryker by 97.1% during the fourth quarter. Venturi Wealth Management LLC now owns 136 shares of the medical technology company’s stock valued at $41,000 after purchasing an additional 67 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on SYK shares. Truist Financial increased their price objective on Stryker from $330.00 to $345.00 and gave the stock a “hold” rating in a research note on Wednesday, January 31st. Evercore ISI increased their price objective on Stryker from $340.00 to $370.00 and gave the company an “outperform” rating in a report on Thursday, April 4th. Royal Bank of Canada increased their price objective on Stryker from $360.00 to $386.00 and gave the company an “outperform” rating in a report on Monday, April 15th. Roth Mkm increased their price objective on Stryker from $345.00 to $348.00 and gave the company a “buy” rating in a report on Wednesday, January 31st. Finally, Canaccord Genuity Group raised Stryker from a “hold” rating to a “buy” rating and set a $360.00 price objective on the stock in a report on Wednesday, January 31st. Three research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $340.67.

Stryker Stock Performance

Shares of NYSE:SYK traded up $0.24 during trading on Thursday, hitting $337.09. 1,615,335 shares of the stock were exchanged, compared to its average volume of 1,286,429. Stryker Co. has a 1-year low of $249.98 and a 1-year high of $361.41. The company has a market capitalization of $128.25 billion, a price-to-earnings ratio of 40.86, a price-to-earnings-growth ratio of 2.70 and a beta of 0.89. The company’s fifty day simple moving average is $349.16 and its 200-day simple moving average is $314.40. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.97 and a current ratio of 1.58.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $3.46 EPS for the quarter, beating the consensus estimate of $3.27 by $0.19. The business had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. Stryker had a return on equity of 22.99% and a net margin of 15.44%. Stryker’s quarterly revenue was up 11.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.00 EPS. Sell-side analysts expect that Stryker Co. will post 11.86 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be paid a $0.80 dividend. This represents a $3.20 dividend on an annualized basis and a yield of 0.95%. The ex-dividend date of this dividend is Wednesday, March 27th. Stryker’s dividend payout ratio is currently 38.79%.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 201,146 shares of the business’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $342.90, for a total value of $68,972,963.40. Following the transaction, the director now owns 3,755,128 shares of the company’s stock, valued at $1,287,633,391.20. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, CAO William E. Berry, Jr. sold 7,690 shares of the business’s stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the completion of the sale, the chief accounting officer now owns 3,675 shares in the company, valued at $1,317,414. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Ronda E. Stryker sold 201,146 shares of the business’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $342.90, for a total value of $68,972,963.40. Following the sale, the director now owns 3,755,128 shares of the company’s stock, valued at approximately $1,287,633,391.20. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 212,109 shares of company stock valued at $72,845,768. 5.90% of the stock is currently owned by corporate insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.